fashion -WSS

fashion

author：comprehensive 2025-09-28 11:56:26 - browse：8696

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Report: NIH

hotspot

focus

WSS

iTeos Therapeutics debuts first data on TIGIT

How to bring more disabled researchers into academia

Scientists successfully use ultrasound imaging to map brain activity

Average age of first period drops to 11.9 years, study shows

IVF, abortion rights issues kick off Biden’s State of the Union

Latest bird flu infection made farmworker sicker than earlier cases

hotspot

fashion

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

As demand for Covid shots wanes, Moderna seeks its next success

Sen. Paul opposes bill to ban Chinese biotechs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Adam's Biotech Scorecard: Do Sarepta's exon

How to save PrEP access — and even expand it

UnitedHealth quietly bought dozens of outpatient centers

Trump demands the U.S. pay no more for drugs than other countries … again

Average age of first period drops to 11.9 years, study shows

Wikipedia

Latest bird flu infection made farmworker sicker than earlier cases

NEJM study link tiny plastics in blood vessels to heart problems

CDC marks new Covid

Heat waves linked to early deliveries, preterm births in new study

iTeos Therapeutics debuts first data on TIGIT

Prosthetic arm enables patients to feel the objects they grip

focus

hotspot

focus

focus